Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN) is a commercial-stage biopharmaceutical company headquartered in Switzerland. Basilea is committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections.
Products, services, technology
We have successfully launched two hospital brands, Cresemba® for the treatment of invasive fungal infections and Zevtera® for the treatment of bacterial infections. In addition, we have preclinical anti-infective assets in our portfolio.